Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-KBusiness Wire • 11 days ago
Exicure, Inc. (Exicure or the Company) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (Nasdaq) on April 17, 2024 notifying the Company that, as a...
Share to Feed
Under the deal terms, Bluejay will have the sole licence to Exicure's patents relevant to hepatitis. Bluejay made an initial payment to Exicure following the deal execution. In
The post Exicure and...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and...
Exicure, Inc. (NASDAQ:XCUR Get Free Report) saw a large growth in short interest in January. As of January 15th, there was short interest totalling 821,100 shares, a growth of 495.9% from the...